APOL1 and kidney disorder: We studied two case-control FSGS discovery cohorts: the first consisted of 434 APOL1-HR FSGS cases and 2398 genetically matched APOL1-HR population controls subjected to Illumina DNA microarray genotyping and imputation; the second included 94 APOL1-HR FSGS cases and 208 genetically matched APOL1-HR controls with whole genome sequencing data (Supplementary Fig. 1), for a total of 528 FSGS cases and 2606 population controls with no known kidney disease.